---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-008956"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T09:23:05.412396+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 reverses cellular decline markers in human cell lines; supports autism and spasmodic dysphonia programs

## Summary
- New preclinical data show Telomir-1 improved cell viability under stress and boosted mitochondrial function in human cell lines.
- Telomir-1 reduced reactive oxygen species (ROS) and restored calcium signaling, limiting oxidative damage and maintaining cellular communication.
- Telomir-1 protected cells from iron- and copper-induced toxicity, which are linked to ROS formation and accelerated aging.
- Findings provide mechanistic foundation for new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD).

## SEC filing metadata
- accession: 0001641172-25-008956
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225008956/0001641172-25-008956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225008956/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-008956
- JSON: https://secwatch.observer/filing/0001641172-25-008956.json
- Plain text: https://secwatch.observer/filing/0001641172-25-008956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.